Department of Neurology, Hôpital Fondation Adolphe de Rothschild, Paris Cedex 19, France.
Service de Neurologie, Sclérose en Plaques, Pathologies de la Myéline et Neuro-Inflammation, Centre de référence des Maladies Inflammatoires Rares du Cerveau et de la Moelle (MIRCEM), Hôpital Neurologique Pierre Wertheimer, Lyon University Hospital, Lyon, France.
Eur J Neurol. 2021 May;28(5):1659-1664. doi: 10.1111/ene.14746. Epub 2021 Feb 19.
The prognosis in myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is a matter of debate. Our aim was to assess the long-term outcomes of patients with MOGAD.
We retrospectively analysed the clinical and paraclinical data of patients from the French nationwide observatory study NOMADMUS who tested positive for MOG antibodies (MOG-IgG) and who had clinical follow-up of at least 8 years from their first episode.
Sixty-one patients (median [range] age at onset 27 [3-69] years), with a median (mean; range) follow-up of 177 (212.8; 98-657) months, were included. Among 58 patients with a relapsing course, 26.3% relapsed in the first year after onset. Of the 61 patients, 90.2% experienced at least one episode of optic neuritis. At last visit, the median (mean; range) Expanded Disability Status Scale (EDSS) score was 1 (2.12; 0-7.5), 12.5% had an EDSS score ≥6 and 37.5% had an EDSS score ≥3. Of 51 patients with final visual acuity (VA) data available, 15.7% had VA ≤0.1 in at least one eye and 25.5% had VA ≤0.5 in at least one eye. Bilateral blindness (VA ≤0.1) was present in 5.9% of patients. Finally, 12.5% of patients presented bladder dysfunction requiring long-term urinary catheterization. No factor associated significantly with a final EDSS score ≥3 or with final VA ≤0.1 was found.
Overall long-term favourable outcomes were achieved in a majority of our patients, but severe impairment, in particular visual damage, was not uncommon.
髓鞘少突胶质细胞糖蛋白（MOG）抗体相关性疾病（MOGAD）的预后存在争议。我们旨在评估 MOGAD 患者的长期结局。
我们回顾性分析了法国全国观察研究 NOMADMUS 中 MOG 抗体（MOG-IgG）检测阳性且自首次发作起临床随访至少 8 年的患者的临床和辅助检查数据。
共纳入 61 例患者（中位[范围]发病年龄 27[3-69]岁），中位（平均；范围）随访时间为 177[212.8；98-657]个月。在 58 例复发病程的患者中，26.3%在发病后 1 年内复发。61 例患者中，90.2%至少发生过一次视神经炎发作。末次随访时，扩展残疾状态量表（EDSS）评分的中位数（平均；范围）为 1（2.12；0-7.5），12.5%的患者 EDSS 评分≥6，37.5%的患者 EDSS 评分≥3。在 51 例最终视力数据可用的患者中，15.7%的患者至少有一眼视力≤0.1，25.5%的患者至少有一眼视力≤0.5。5.9%的患者存在双眼失明（视力≤0.1）。最后，12.5%的患者存在需要长期留置导尿管的膀胱功能障碍。未发现任何因素与最终 EDSS 评分≥3 或最终视力≤0.1显著相关。
我们的大多数患者总体上取得了良好的长期结局，但严重的损害，特别是视力损害并不少见。
